Targeted therapeutics (in the form of ADCs : )) have arrived!

ADC number #9 approved. This one against refractory/relapsed multiple myeloma. https://www.cancernetwork.com/view/fda-approves-belantamab-mafodotin-blmf-to-treat-relapsed-refractory-multiple-myeloma